We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

98 hedge funds and large institutions have $623M invested in Krystal Biotech in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 47 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 30

6% more capital invested

Capital invested by funds: $589M → $623M (+$34.1M)

1.31% more ownership

Funds ownership: 72.17% → 73.48% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less funds holding

Funds holding: 110 → 98 (-12)

75% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 16

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.06M

Holders
98
Holders Change
-12
Holders Change %
-10.91%
% of All Funds
1.98%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
47
Reduced
30
Closed
16
Calls
–
Puts
$1.06M
Net Calls
-$1.06M
Net Calls Change
-$986K

Top Buyers

Rank Fund Capital Flow
1
PAMU
Pictet Asset Management (UK)
United Kingdom
+$11.9M
2
Victory Capital Management
Victory Capital Management
Texas
+$10.7M
3
NIP
Nicholas Investment Partners
California
+$7.94M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.41M
5
RG
Redmile Group
California
+$4M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$23.4M
2
Wells Fargo
Wells Fargo
California
-$7.61M
3
State Street
State Street
Massachusetts
-$4.45M
4
BBA
Baker Bros. Advisors
New York
-$1.84M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.16M +$875K +20,148 +26%
Handelsbanken Fonder
27
Handelsbanken Fonder
Sweden
$3.87M – – –
JP Morgan Chase
28
JP Morgan Chase
New York
$3.62M +$791K +18,223 +27%
SST
29
S Squared Technology
New York
$3.45M +$434K +10,000 +14%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.69M +$152K +3,502 +6%
Fidelity International
31
Fidelity International
Bermuda
$2.63M +$3.3K +76 +0.1%
SG Americas Securities
32
SG Americas Securities
New York
$2.45M +$1.57M +36,203 +175%
Verition Fund Management
33
Verition Fund Management
Connecticut
$2.41M -$454K -10,457 -16%
Aviva
34
Aviva
United Kingdom
$2.27M -$114K -2,621 -5%
Neuberger Berman Group
35
Neuberger Berman Group
New York
$2.2M +$347K +8,000 +19%
N
36
Nuveen
North Carolina
$2.02M +$120K +2,774 +6%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$2.02M +$482K +11,096 +31%
GECH
38
Garnet Equity Capital Holdings
New York
$1.72M – – –
William Blair & Company
39
William Blair & Company
Illinois
$1.55M -$603K -13,880 -28%
MAM
40
Martingale Asset Management
Massachusetts
$1.48M -$999K -22,999 -40%
JGC
41
J. Goldman & Co
New York
$1.45M -$501K -11,530 -26%
MOACM
42
Mutual of America Capital Management
New York
$1.25M +$115K +2,638 +10%
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.24M +$21.7K +500 +2%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$1.24M +$71.2K +1,640 +6%
BBHC
45
Brown Brothers Harriman & Co
New York
$1.16M – – –
Barclays
46
Barclays
United Kingdom
$1.15M +$864K +19,890 +292%
Wells Fargo
47
Wells Fargo
California
$1.09M -$7.61M -175,211 -87%
AA
48
ALPS Advisors
Colorado
$1.08M +$58.9K +1,357 +6%
Citadel Advisors
49
Citadel Advisors
Florida
$1.04M +$113K +2,595 +12%
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$969K -$543K -12,500 -36%
1
2
3 4 5

KRYS Hedge Fund Activity: Q3 2020 in Review

98 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2020, worth a combined $623M — up 5.8% from $589M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of KRYS and 4 opened new positions — a net loss of 12 holders — while 30 trimmed existing stakes and 47 added.

The largest buyer was Pictet Asset Management (UK), adding an estimated $11.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $23.4M.

  • 98 institutional investors held Krystal Biotech (KRYS) as of Q3 2020, down from 110 in Q2 2020.
  • Funds reported $623M of Krystal Biotech stock for Q3 2020, up 5.8% quarter-over-quarter.
  • 4 funds opened new Krystal Biotech positions in Q3 2020 and 16 closed out, a net change of -12 holders.
  • The largest Krystal Biotech buyer in Q3 2020 was Pictet Asset Management (UK), an estimated $11.9M added.
  • The largest Krystal Biotech seller in Q3 2020 was T. Rowe Price Associates, an estimated $23.4M sold.

Based on aggregated 13F filings for Q3 2020.